Nicotinic-Purinergic Modulation of Bladder Contraction
膀胱收缩的烟碱-嘌呤能调节
基本信息
- 批准号:7020746
- 负责人:
- 金额:$ 30.03万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2005
- 资助国家:美国
- 起止时间:2005-03-01 至 2010-02-28
- 项目状态:已结题
- 来源:
- 关键词:acetylcholineatropinebinding sitescalcium fluxcalcium indicatorcarbacholgenetically modified animalsimmunocytochemistrylaboratory mousemuscle contractionneurogenic urinary bladder disorderneuroregulationnicotinic receptorspolymerase chain reactionprotein isoformsprotein protein interactionpurinergic receptorreceptor expressionsmooth musclespinal cord injuryurinary bladder
项目摘要
DESCRIPTION (provided by applicant): This proposal is based on the unusual finding in animal models (rat, mouse) that nicotinic receptor agonists significantly enhance the inhibitory action of muscarinic receptor antagonists (atropine, 4-DAMP) on neurally evoked rat bladder contractions, presumably by impairing the non-adrenergic non-cholinergic (NANC component of the contraction. This interaction can be evoked by mixed nicotinic-muscarinic agonists like carbachol, or the cholinergic transmitter acetylcholine, indicating that this finding may have pathophysiological significance, particularly if modulated following bladder injury or insult. For example, the nicotinic-purinergic interaction appears to be constitutively active following spinal cord injury as rat bladders exhibit a higher sensitivity to muscarinic antagonists and, thus, become more 'cholinergic" as compared to normal bladders. In addition, after nicotinic-purinergic interaction the normal rat bladder smooth muscle exhibits much smaller contractions to the purinergic agonist, alpha-beta-methylene ATP suggesting that P2X1 receptor mechanisms may be impacted. We propose to investigate the role of purinergic P2X1 receptors in the nicotinic-purinergic interaction by: 1) utilizing pharmacological methods on the neurally and chemically evoked bladder contractions and 2) measuring changes in intracellular Ca2+ levels by calcium imaging. In addition, we will explore mechanisms underlying changes in nicotinic-purinergic interaction that occur in bladders after spinal cord injury or after bladder outlet obstruction. We hypothesize that the nicotinic binding site is plastic and is already activated in neurogenic bladders, thus explaining why atropine is more effective in inhibiting the neurally evoked contractions. We will utilize RT-PCR and immunohistochemical techniques to identify nicotinic receptor subtypes in normal bladders and to examine whether expression of these specific receptors is altered with SCI or obstruction. Depending on the nicotinic subunits identified with RT-PCR, specific ligands to measure nicotinic receptor binding affinity will be used to more fully characterize the nature of this unusual interaction. Finally, we will utilize readily available nicotinic receptor knockout mice to functionally confirm the modulatory role of specific nicotinic receptors on mouse bladder contractions.
描述(由申请人提供):该提案是基于动物模型(大鼠,小鼠)中的异常发现,即烟碱受体激动剂显着增强了毒蕈碱受体拮抗剂(阿托品,4-DAMP)对神经诱发的大鼠膀胱收缩的抑制作用,这可能会损害这种非脑蛋白(can)的综合(can cancorment n Interastion(can)。烟碱毒素激动剂(如卡巴醇)或胆碱能发射器乙酰胆碱的混合诱发,表明该发现可能具有病理生理学意义,尤其是在膀胱损伤后调节或侮辱后,烟碱疗法的表现更高。与正常膀胱相比,拮抗剂,因此变得更加“胆碱能”。此外,在烟碱 - 纯素能相互作用之后,正常大鼠膀胱平滑肌表现出对嘌呤能激动剂的收缩较小,呈嘌呤甲基 - 甲基甲基乙烯ATP,表明P2X1受体机制可能会影响P2X1受体机制。我们建议通过以下方式研究嘌呤能P2X1受体在烟碱 - 纯良学相互作用中的作用:1)通过钙成像利用药理学方法对神经和化学诱发的膀胱收缩和化学诱发的膀胱收缩和2)测量细胞内Ca2+水平的变化。此外,我们将探索脊髓损伤或膀胱出口障碍物后膀胱中发生的烟碱 - 纯净相互作用变化的机制。我们假设烟碱结合位点是塑性的,并且已经在神经源性膀胱中被激活,从而解释了为什么阿托品在抑制神经诱发的收缩方面更有效。我们将利用RT-PCR和免疫组织化学技术来鉴定正常膀胱中的烟碱受体亚型,并检查这些特定受体的表达是否随SCI或阻塞而改变。根据用RT-PCR鉴定的烟碱亚基,测量烟碱受体结合亲和力的特定配体将用于更充分地表征这种异常相互作用的性质。最后,我们将利用易于使用的烟碱受体基因敲除小鼠在功能上确认特定烟碱受体在小鼠膀胱收缩上的调节作用。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
GEORGE T SOMOGYI其他文献
GEORGE T SOMOGYI的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('GEORGE T SOMOGYI', 18)}}的其他基金
Nicotinic-Purinergic Modulation of Bladder Contraction
膀胱收缩的烟碱-嘌呤能调节
- 批准号:
7198064 - 财政年份:2005
- 资助金额:
$ 30.03万 - 项目类别:
Nicotinic-Purinergic Modulation of Bladder Contraction
膀胱收缩的烟碱-嘌呤能调节
- 批准号:
6859996 - 财政年份:2005
- 资助金额:
$ 30.03万 - 项目类别:
Nicotinic-Purinergic Modulation of Bladder Contraction
膀胱收缩的烟碱-嘌呤能调节
- 批准号:
7380089 - 财政年份:2005
- 资助金额:
$ 30.03万 - 项目类别:
Nicotinic-Purinergic Modulation of Bladder Contraction
膀胱收缩的烟碱-嘌呤能调节
- 批准号:
7572952 - 财政年份:2005
- 资助金额:
$ 30.03万 - 项目类别:
相似国自然基金
ZNRF1在阿托品治疗近视疗效差异性中的作用机理
- 批准号:
- 批准年份:2022
- 资助金额:30 万元
- 项目类别:青年科学基金项目
ZNRF1在阿托品治疗近视疗效差异性中的作用机理
- 批准号:82201229
- 批准年份:2022
- 资助金额:30.00 万元
- 项目类别:青年科学基金项目
阿托品控制儿童近视基因组学研究
- 批准号:82171089
- 批准年份:2021
- 资助金额:57.00 万元
- 项目类别:面上项目
MAPK/ERK/HIF-1a通路介导阿托品抑制豚鼠实验性近视的机制研究
- 批准号:
- 批准年份:2021
- 资助金额:54 万元
- 项目类别:面上项目
阿托品控制儿童近视基因组学研究
- 批准号:
- 批准年份:2021
- 资助金额:57 万元
- 项目类别:面上项目
相似海外基金
A Vitamin K analog countermeasure for organophosphate poisoning
维生素 K 类似物治疗有机磷中毒的对策
- 批准号:
10602913 - 财政年份:2023
- 资助金额:
$ 30.03万 - 项目类别:
Identification and optimization of verapamil as a novel neuroprotective and anti-inflammatory agent for reducing long-term neurological morbidities following organophosphate-induced status epilepticus
维拉帕米作为新型神经保护和抗炎剂的鉴定和优化,用于减少有机磷引起的癫痫持续状态后的长期神经系统发病率
- 批准号:
10727765 - 财政年份:2023
- 资助金额:
$ 30.03万 - 项目类别:
Topical Eyedrops Increasing Lysyl Oxidase Activity to Control Myopia
局部滴眼剂增加赖氨酰氧化酶活性来控制近视
- 批准号:
10603432 - 财政年份:2023
- 资助金额:
$ 30.03万 - 项目类别:
Long-acting aldicarb hydrolase as a medical countermeasure for aldicarb poisoning
长效涕灭威水解酶作为涕灭威中毒的医学对策
- 批准号:
10724752 - 财政年份:2023
- 资助金额:
$ 30.03万 - 项目类别:
Novel oxime antidotes for an organophosphate insecticide requiring bioactivation
用于需要生物活化的有机磷杀虫剂的新型肟解毒剂
- 批准号:
10629574 - 财政年份:2023
- 资助金额:
$ 30.03万 - 项目类别: